Global Gastroenterology Market

Gastroenterology Market Size, Share, Growth Analysis, By Type (Branded, Generics), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Application (Crohn'S Disease, Ulcerative Colitis), By Route Of Administration (Injectable, Oral & Others), By Region - Industry Forecast 2026-2033

Report ID: SQSG35I2028 | Region: Global | Published Date: November, 2025
Pages: 165 |Tables: 96 |Figures: 76

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Gastroenterology Market size was valued at USD 39.61 Billion in 2024 and is poised to grow from USD 41.94 Billion in 2025 to USD 66.35 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026–2033). 

    The market for gastrointestinal medicines is moderately fragmented. To increase their market share, the market players have widely used competition sustainability methods such as new product development and regional and distribution channel expansion. Furthermore, a greater emphasis on supply chain management and operational improvement has made it easier for major companies to keep a competitive edge. 'AbbVie Inc. (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AstraZeneca plc (UK) ', 'Bayer AG (Germany) ', 'Pfizer Inc. (USA) ', 'Johnson & Johnson (USA) ', 'Novartis AG (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Sanofi S.A. (France) ', 'GlaxoSmithKline plc (UK) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Teva Pharmaceutical Industries Limited (Israel) ', 'Boston Scientific Corporation (USA) ', 'Medtronic plc (Ireland) ', 'Olympus Corporation (Japan) ', 'Fujifilm Corporation (Japan) ', 'Stryker Corporation (USA) ', 'Nestle Health Science (Switzerland) ', 'Danone S.A. (France) '

    Rising incidence of gastrointestinal diseases: Globally, the prevalence of gastrointestinal conditions such gallstones, ulcerative colitis, fissure, hemorrhoids, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD) has dramatically grown. The main causes of the rising prevalence of chronic and acute gastrointestinal illnesses are poor diet, a sedentary lifestyle, stress, food sensitivity, and bacterial or viral infections. Numerous drugs, such as antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics, are increasingly in demand to treat various gastrointestinal disorders and prevent subsequent medical consequences related to the diseases. This is driving up the demand for different classes or types of pharmaceuticals to treat gastrointestinal ailments, which is driving up the growth of the global market for therapeutics for gastrointestinal diseases.

    The demand for developing cutting-edge medicines is being driven by the increase in severe to moderate gastrointestinal disorders, such as ulcerative colitis, Crohn's disease, and other gastrointestinal ailments. In order to expand their product pipeline, pharmaceutical and biotechnology businesses are concentrating on R&D to find and create novel medications for the treatment of gastrointestinal illnesses. The global market for gastrointestinal illnesses therapeutics is anticipated to see growth prospects during the forecast period as a result of firms' increasing focus on the development of revolutionary innovative therapies for effectively treating gastrointestinal ailments. During the forecast period, the growing development of gastrointestinal illness medications by regional and international vendors is anticipated to significantly contribute to the growth of the worldwide gastrointestinal disorders therapeutics market.

    Based on the region, the North American region currently dominates the global gastroenterology market. The market in North America had the biggest share in 2021 and is anticipated to hold that position during the projected period. Technological advancements, an unprecedented change in lifestyle leading to a higher incidence of gastrointestinal diseases, an increase in the number of geriatric and obese people, and rising research and development activities with the presence of key market players are some of the factors that are fueling the market growth in the North American region. Additionally, the government's measures to prevent and treat gastrointestinal disorders are anticipated to propel the market. For instance, UNICEF and WHO's Integrated Global Action Plan for Diarrhea aims to reduce the number of child deaths that can be prevented due to diarrhea by providing interventions and services to increase awareness and offer access to treatment and preventative measures.

    Related Reports

    Medical Gas Market
    Buy Now GET FREE SAMPLE
    Bowel Management Systems Market
    Buy Now GET FREE SAMPLE
    Medical Gas Equipment Market
    Buy Now GET FREE SAMPLE
    Patient Portal Market
    Buy Now GET FREE SAMPLE
    Digestive Health Products Market
    Buy Now GET FREE SAMPLE
    Biologics Market
    Buy Now GET FREE SAMPLE
    Patient Infotainment Terminal Market
    Buy Now GET FREE SAMPLE
    Medical Waste Management Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Gastroenterology Market

    Report ID: SQSG35I2028

    $5,300
    BUY NOW